Logo Image
|Articles|July 11, 2019

Novotech CRO Partners Skin Research Institute

Novotech, an Asia-Pacific CRO, has further strengthened its presence in the region through a Partnership with the Skin Research Institute of Singapore (SRIS). With this partnership, the two groups will be working together to promote combined capabilities in skin research clinical trials.

The Partnership formalizes a long-standing working relationship between the two.

SRIS was established as a collaboration between Agency for Science, Technology and Research (A*STAR), National Healthcare Group (NHG) and Nanyang Technological University (NTU) to conduct high impact, inter-disciplinary skin research that would translate into improved health outcomes and quality of life.

Novotech now has over 20 significant Partnerships with some of the leading medical institutions in the region. The Partnership Program is designed to bring access to investigators, KOLs, and up to 4 million patients for its international biotech clients.

Novotech CEO Dr John Moller said the Partnership with SRIS will support the increasing demand from biotech clients for skin disorder studies in the Asia-Pacific region.

For more information go to https://novotech-cro.com/

Related to this article

View more
© C Davids/peopleimages.com - © C Davids/peopleimages.com - stock.adobe.com
What "Patient Voice" Actually Requires: Beyond the Buzzword
The clinical research industry talks about patient-centeredness constantly but embeds it too late, too narrowly, and without clear ownership, and the cost shows up in enrollment failures, protocol deviations, and outcomes that don't reflect what patients actually care about.
Read more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more